Literature DB >> 14715803

Serodiagnosis of chronic and acute Chagas' disease with Trypanosoma cruzi recombinant proteins: results of a collaborative study in six Latin American countries.

Eufrosina S Umezawa1, Alejandro O Luquetti, Gabriela Levitus, Carlos Ponce, Elisa Ponce, Diana Henriquez, Susana Revollo, Bertha Espinoza, Octavio Sousa, Baldip Khan, José Franco da Silveira.   

Abstract

An enzyme-linked immunosorbent assay to diagnose Chagas' disease by a serological test was performed with Trypanosoma cruzi recombinant antigens (JL8, MAP, and TcPo). High sensitivity (99.4%) and specificity (99.3%) were obtained when JL8 was combined with MAP (JM) and tested with 150 serum samples from chagasic and 142 nonchagasic individuals. Moreover, JM also diagnosed 84.2% of patients in the acute phase of T. cruzi infection.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14715803      PMCID： PMC321695          DOI： 10.1128/JCM.42.1.449-452.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  32 in total

Review 1.  Intervention strategies to reduce the risk of transfusion-transmitted Trypanosoma cruzi infection in the United States.

Authors:  I A Shulman
Journal:  Transfus Med Rev       Date:  1999-07

2.  Serological confirmation of Chagas' disease by a recombinant and peptide antigen line immunoassay: INNO-LIA chagas.

Authors:  A Saez-Alquézar; E C Sabino; N Salles; D F Chamone; F Hulstaert; H Pottel; E Stoops; M Zrein
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  Evaluation of recombinant antigens for serodiagnosis of Chagas' disease in South and Central America.

Authors:  E S Umezawa; S F Bastos; M E Camargo; L M Yamauchi; M R Santos; A Gonzalez; B Zingales; M J Levin; O Sousa; R Rangel-Aldao; J F da Silveira
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

4.  Enzyme-linked immunosorbent assay for serological diagnosis of Chagas' disease employing a Trypanosoma cruzi recombinant antigen that consists of four different peptides.

Authors:  A W Ferreira; Z R Belem; E A Lemos; S G Reed; A Campos-Neto
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

5.  Antibodies against the carboxyl-terminal end of the Trypanosoma cruzi ribosomal P proteins are pathogenic.

Authors:  P López Bergami; J Scaglione; M J Levin
Journal:  FASEB J       Date:  2001-12       Impact factor: 5.191

Review 6.  Chagas disease: recombinant Trypanosoma cruzi antigens for serological diagnosis.

Authors:  J F da Silveira; E S Umezawa; A O Luquetti
Journal:  Trends Parasitol       Date:  2001-06

7.  A multi-epitope synthetic peptide and recombinant protein for the detection of antibodies to Trypanosoma cruzi in radioimmunoprecipitation-confirmed and consensus-positive sera.

Authors:  R L Houghton; D R Benson; L D Reynolds; P D McNeill; P R Sleath; M J Lodes; Y A Skeiky; D A Leiby; R Badaro; S G Reed
Journal:  J Infect Dis       Date:  1999-05       Impact factor: 5.226

Review 8.  Prevention of transfusional Trypanosoma cruzi infection in Latin America.

Authors:  G A Schmunis
Journal:  Mem Inst Oswaldo Cruz       Date:  1999       Impact factor: 2.743

9.  Enzyme-linked immunosorbent assay with Trypanosoma cruzi excreted-secreted antigens (TESA-ELISA) for serodiagnosis of acute and chronic Chagas' disease.

Authors:  E S Umezawa; M S Nascimento; A M Stolf
Journal:  Diagn Microbiol Infect Dis       Date:  2001-03       Impact factor: 2.803

Review 10.  Clinical and epidemiological aspects of Chagas disease.

Authors:  A Prata
Journal:  Lancet Infect Dis       Date:  2001-09       Impact factor: 25.071
View more
  24 in total

1.  Severe invalidating pain syndrome associated with benznidazole therapy for Chagas' disease.

Authors:  Concepción Moll; Pilar Peris; Asunción Moreno; José Muñoz; Nuria Guañabens
Journal:  Clin Rheumatol       Date:  2007-08-17       Impact factor: 2.980

2.  Comparison of recombinant Trypanosoma cruzi peptide mixtures versus multiepitope chimeric proteins as sensitizing antigens for immunodiagnosis.

Authors:  Cecilia Camussone; Verónica Gonzalez; María S Belluzo; Nazarena Pujato; María E Ribone; Claudia M Lagier; Iván S Marcipar
Journal:  Clin Vaccine Immunol       Date:  2009-04-01

3.  Serological Diagnosis of Chronic Chagas Disease: Is It Time for a Change?

Authors:  Alba Abras; Montserrat Gállego; Teresa Llovet; Silvia Tebar; Mercedes Herrero; Pere Berenguer; Cristina Ballart; Carmen Martí; Carmen Muñoz
Journal:  J Clin Microbiol       Date:  2016-04-06       Impact factor: 5.948

4.  Enhanced classification of Chagas serologic results and epidemiologic characteristics of seropositive donors at three large blood centers in Brazil.

Authors:  Ester C Sabino; Nanci A Salles; Moussa Sarr; Angela M Barreto; Marcio Oikawa; Cláudia D Oliveira; Silvana C Leao; Anna B Carneiro-Proietti; Brian Custer; Michael P Busch
Journal:  Transfusion       Date:  2010-12       Impact factor: 3.157

5.  Characterization of an immunodominant antigenic epitope from Trypanosoma cruzi as a biomarker of chronic Chagas' disease pathology.

Authors:  M Carmen Thomas; Ana Fernández-Villegas; Bartolomé Carrilero; Concepción Marañón; Daniel Saura; Oscar Noya; Manuel Segovia; Belkisyolé Alarcón de Noya; Carlos Alonso; Manuel Carlos López
Journal:  Clin Vaccine Immunol       Date:  2011-12-07

Review 6.  Between a bug and a hard place: Trypanosoma cruzi genetic diversity and the clinical outcomes of Chagas disease.

Authors:  Louisa A Messenger; Michael A Miles; Caryn Bern
Journal:  Expert Rev Anti Infect Ther       Date:  2015-08       Impact factor: 5.091

7.  Lateral flow immunoassay for diagnosis of Trypanosoma cruzi infection with high correlation to the radioimmunoprecipitation assay.

Authors:  Raymond L Houghton; Yvonne Y Stevens; Kathryn Hjerrild; Jeff Guderian; Masahiko Okamoto; Mazbahul Kabir; Steven G Reed; David A Leiby; W John W Morrow; Myriam Lorca; Syamal Raychaudhuri
Journal:  Clin Vaccine Immunol       Date:  2009-02-11

8.  Performance of six diagnostic tests to screen for Chagas disease in blood banks andprevalence of Trypanosoma cruzi infection among donors with inconclusive serologyscreening based on the analysis of epidemiological variables.

Authors:  Gilberto de Araujo Pereira; Francisco Louzada-Neto; Valdirene de Fátima Barbosa; Márcia Maria Ferreira-Silva; Helio de Moraes-Souza
Journal:  Rev Bras Hematol Hemoter       Date:  2012

9.  Use of a Latent Class Analysis in the Diagnosis of Chronic Chagas Disease in the Washington Metropolitan Area.

Authors:  Yagahira E Castro-Sesquen; Antonella Saldaña; Dhayanna Patino Nava; Tabitha Bayangos; Diana Paulette Evans; Kelly DeToy; Alexia Trevino; Rachel Marcus; Caryn Bern; Robert H Gilman; Kawsar R Talaat
Journal:  Clin Infect Dis       Date:  2021-05-04       Impact factor: 9.079

10.  Evaluation of in-house ELISA using Trypanosoma cruzi lysate and recombinant antigens for diagnosis of Chagas disease and discrimination of its clinical forms.

Authors:  Silvia A Longhi; Silvia B Brandariz; Sonia O Lafon; Leticia L Niborski; Alejandro O Luquetti; Alejandro G Schijman; Mariano J Levin; Karina A Gómez
Journal:  Am J Trop Med Hyg       Date:  2012-08       Impact factor: 2.345
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.